car-t vs bispecifics: the best immune approach to replace asct
Published 3 years ago • 190 plays • Length 6:40Download video MP4
Download video MP3
Similar videos
-
2:52
replacing asct: car-t or bispecific antibodies?
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
1:04
bispecifics & car-t therapy in dlbcl: sequencing and selecting between these agents
-
1:14
the car t-cell strategy vs bispecific antibodies
-
6:38
comparison of the safety & efficacy of car-t therapy vs bispecifics in r/r multiple myeloma
-
4:49
car-t vs bispecifics in triple-class refractory multiple myeloma: comparing outcomes & sequencing
-
3:33
determining the optimal sequencing of bispecifics and car-t cells in patients with myeloma
-
12:59
advances in car-t cell therapy - creative biolabs
-
11:18
car-t cells: engineered cancer killers
-
4:47
efficacy of novel t-cell bispecific engaging antibody, cd20-tcb (rg6026), for r/r nhl
-
2:19
the addition of venetoclax to hyper-cvad-nelarabine and pegylated asparagine in t-all
-
1:42
how to best sequence bispecific antibodies and car-t therapy in multiple myeloma
-
3:06
car-t and bites – which targets belong in clinical practice?
-
4:35
bispecific antibodies vs car t-cells for r/r multiple myeloma
-
2:52
comparing the efficacy and curative potential of car-t therapy & bispecific antibodies in r/r dlbcl
-
6:02
car-t vs. bites in b-cell malignancies
-
4:27
the possibility of combining car-t therapy and bispecific antibodies in the treatment of nhl
-
2:22
combining car-ts & bispecific antibodies
-
0:45
bispecific car t-cell therapy: combining anti-cd19 and cd22 car t-cells
-
0:50
the fast-changing field of car-t therapy
-
12:15
car-t vs bispecific antibodies for lymphoma
-
1:23
advantages of bispecific antibodies over car-t therapy in lbcl